Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 85.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,986 shares of the company’s stock after purchasing an additional 23,086 shares during the period. Landscape Capital Management L.L.C.’s holdings in Apellis Pharmaceuticals were worth $1,595,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of APLS. Cinctive Capital Management LP acquired a new position in Apellis Pharmaceuticals in the 4th quarter worth approximately $2,776,000. Trexquant Investment LP acquired a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth $6,478,000. Geode Capital Management LLC raised its holdings in shares of Apellis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock worth $58,699,000 after purchasing an additional 28,426 shares during the last quarter. National Bank of Canada FI lifted its position in Apellis Pharmaceuticals by 266,361.5% during the fourth quarter. National Bank of Canada FI now owns 1,385,600 shares of the company’s stock valued at $44,214,000 after purchasing an additional 1,385,080 shares during the period. Finally, Pictet Asset Management Holding SA boosted its holdings in Apellis Pharmaceuticals by 16.7% in the fourth quarter. Pictet Asset Management Holding SA now owns 347,854 shares of the company’s stock valued at $11,100,000 after purchasing an additional 49,901 shares during the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now owns 138,730 shares of the company’s stock, valued at $3,482,123. This trade represents a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $62,279.00. Following the transaction, the chief financial officer now owns 88,100 shares of the company’s stock, valued at approximately $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,054 shares of company stock worth $1,952,719 over the last quarter. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Price Performance

APLS opened at $19.97 on Friday. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $19.76 and a fifty-two week high of $57.85. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company’s 50-day moving average price is $26.22 and its 200 day moving average price is $29.05. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same period last year, the company earned ($0.73) earnings per share. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. As a group, sell-side analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on APLS. The Goldman Sachs Group decreased their price objective on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Royal Bank of Canada lowered their price objective on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research report on Monday, March 3rd. Scotiabank lifted their target price on shares of Apellis Pharmaceuticals from $30.00 to $31.00 and gave the company a “sector perform” rating in a report on Wednesday. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, Wedbush dropped their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $45.59.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).